Boston Scientific’s acquisition of Relievant Medsystems Inc. will give the company’s slow-growing neuromodulation business immediate entry into the expanding vertebrogenic pain market.
On 19 September, Boston Scientific announced a definitive agreement to acquire Relievant, a privately held Minneapolis company, for $850m plus undisclosed payments tied to sales milestones over the next three...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?